E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Oxford, UK, 18 December 2017: e-therapeutics plc (AIM: ETX), the computer-based drug discovery platform company, announces that it has received notifications from each of its directors that they have purchased, in aggregate, 670,000 shares in the Company at a price of 8.9 pence per share. The purchases took place on 15 December 2017.
The number of ordinary shares purchased by each director is set out below:
Director |
Number of shares purchased |
Iain Ross |
200,000 |
Ray Barlow |
100,000 |
Steve Medlicott |
200,000 |
Professor Trevor Jones |
50,000 |
Christine Soden |
120,000 |
Mr Medlicott purchased the shares through his self-invested personal pension (SIPP) and, following these trades, the beneficial interests of those directors in ordinary shares of ETX are as follows:
Director |
Number of shares held |
Percentage of issued share capital |
Iain Ross |
1,450,000 |
0.54% |
Ray Barlow |
1,200,000 |
0.45% |
Steve Medlicott |
1,450,000 |
0.54% |
Professor Trevor Jones |
262,261 |
0.10% |
Christine Soden |
120,000 |
0.04% |
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
a) |
Name |
Iain Ross |
2 |
Reason for the notification |
|
a) |
Position/status |
Non-Executive Chairman |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
e-therapeutics plc |
b) |
LEI |
21380049RHSSJXWKYT18 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
200,000 ordinary shares at a price of 8.9 pence per share |
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
e) |
Date of the transaction |
15 December 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM (XLON) |
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
a) |
Name |
Ray Barlow |
2 |
Reason for the notification |
|
a) |
Position/status |
Chief Executive Officer/Director |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
e-therapeutics plc |
b) |
LEI |
21380049RHSSJXWKYT18 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
100,000 ordinary shares at a price of 8.9 pence per share |
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
e) |
Date of the transaction |
15 December 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM (XLON) |
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
a) |
Name |
Steve Medlicott |
2 |
Reason for the notification |
|
a) |
Position/status |
Chief Finance Officer/Director |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
e-therapeutics plc |
b) |
LEI |
21380049RHSSJXWKYT18 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) |
Nature of the transaction |
Purchase of shares through self-invested personal pension (SIPP) |
c) |
Price(s) and volume(s) |
200,000 ordinary shares at a price of 8.9 pence per share |
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
e) |
Date of the transaction |
15 December 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM (XLON) |
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
a) |
Name |
Professor Trevor Jones |
2 |
Reason for the notification |
|
a) |
Position/status |
Non-Executive Director |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
e-therapeutics plc |
b) |
LEI |
21380049RHSSJXWKYT18 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
50,000 ordinary shares at a price of 8.9 pence per share |
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
e) |
Date of the transaction |
15 December 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM (XLON) |
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
a) |
Name |
Christine Soden |
2 |
Reason for the notification |
|
a) |
Position/status |
Non-Executive Director |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
e-therapeutics plc |
b) |
LEI |
21380049RHSSJXWKYT18 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
120,000 ordinary shares at a price of 8.9 pence per share |
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
e) |
Date of the transaction |
15 December 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM (XLON) |
For further information, please contact:
e-therapeutics plc Ray Barlow, Chief Executive Officer Steve Medlicott, Finance Director
|
Tel: +44 (0) 1993 883 125
|
Numis Securities Limited Michael Meade/Freddie Barnfield James Black (Corporate Broking)
|
Tel: +44 (0) 207 260 1000
|
Instinctif Partners Melanie Toyne Sewell/Alex Shaw |
Tel: +44 (0) 207 457 2020 |
About e-therapeutics plc
We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.
Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.
e-therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.